{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:02:10Z","timestamp":1779904930864,"version":"3.53.1"},"reference-count":35,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2025,9,30]]},"DOI":"10.1536\/ihj.25-051","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:07:39Z","timestamp":1757542059000},"page":"895-903","source":"Crossref","is-referenced-by-count":1,"title":["Esaxerenone Attenuates Atherogenesis and Vascular Dysfunction in Apolipoprotein E-Deficient Mice"],"prefix":"10.1536","volume":"66","author":[{"given":"Juri","family":"Maeda","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uugantsetseg","family":"Munkhjargal","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyunbileg","family":"Bavuu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiju","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.","DOI":"10.1056\/NEJM199901143400207"},{"key":"2","unstructured":"2. Aikawa M, Libby P. Atherosclerotic plaque inflammation: the final frontier? Can J Cardiol 2004; 20: 631-4."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.","DOI":"10.1056\/NEJMra043430"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Paoletti R, Gotto AM Jr., Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation 2004; 109: Iii20-6.","DOI":"10.1161\/01.CIR.0000131514.71167.2e"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Nehme A, Zibara K. Cellular distribution and interaction between extended renin-angiotensin-aldosterone system pathways in atheroma. Atherosclerosis 2017; 263: 334-42.","DOI":"10.1016\/j.atherosclerosis.2017.05.029"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep 2014; 16: 431.","DOI":"10.1007\/s11906-014-0431-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Durante A, Peretto G, Laricchia A, <i>et al<\/i>. Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des 2012; 18: 981-1004.","DOI":"10.2174\/138161212799436467"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamada M, Mendell J, Takakusa H, Shimizu T, Ando O. Pharmacokinetics, Metabolism, and Excretion of [(14)C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans. Drug Metab Dispos 2019; 47: 340-9.","DOI":"10.1124\/dmd.118.084897"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension 2020; 75: 51-8.","DOI":"10.1161\/HYPERTENSIONAHA.119.13569"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol 2015; 769: 266-73.","DOI":"10.1016\/j.ejphar.2015.11.028"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Li L, Guan Y, Kobori H, <i>et al<\/i>. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats. Hypertens Res 2019; 42: 769-78.","DOI":"10.1038\/s41440-018-0187-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ito S, Kashihara N, Shikata K, <i>et al<\/i>. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial. Clin J Am Soc Nephrol 2020; 15: 1715-27.","DOI":"10.2215\/CJN.06870520"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bavuu O, Fukuda D, Ganbaatar B, <i>et al<\/i>. Esaxerenone, a selective mineralocorticoid receptor blocker, improves insulin sensitivity in mice consuming high-fat diet. Eur J Pharmacol 2022; 931: 175190.","DOI":"10.1016\/j.ejphar.2022.175190"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Munkhjargal U, Fukuda D, Ganbaatar B, <i>et al<\/i>. A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL\/6 Mice. J Atheroscler Thromb 2023; 30: 326-34.","DOI":"10.5551\/jat.63382"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lloyd DJ, McCormick J, Helmering J, <i>et al<\/i>. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-\/-Lepob\/ob mice devoid of ApoE or Ldlr. Am J Physiol Endocrinol Metab 2008; 294: E496-505.","DOI":"10.1152\/ajpendo.00509.2007"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Hara T, Fukuda D, Tanaka K, <i>et al<\/i>. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 2015; 242: 639-46.","DOI":"10.1016\/j.atherosclerosis.2015.03.023"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pham PT, Fukuda D, Yagi S, <i>et al<\/i>. Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice. Sci Rep 2019; 9: 11206.","DOI":"10.1038\/s41598-019-47474-0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Matsumoto S, Shimabukuro M, Fukuda D, <i>et al<\/i>. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)\/Thr(497) of endothelial nitric oxide synthase in diabetic mice. Cardiovasc Diabetol 2014; 13: 30.","DOI":"10.1186\/1475-2840-13-30"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens 2012; 25: 514-23.","DOI":"10.1038\/ajh.2011.245"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shibata S, Nagase M, Yoshida S, <i>et al<\/i>. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14: 1370-6.","DOI":"10.1038\/nm.1879"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Nishiyama A, Yao L, Fan Y, <i>et al<\/i>. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005; 45: 710-6.","DOI":"10.1161\/01.HYP.0000154681.38944.9a"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-64.","DOI":"10.1161\/01.HYP.0000255636.11931.a2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Fiebeler A, Luft FC. The mineralocorticoid receptor and oxidative stress. Heart Fail Rev 2005; 10: 47-52.","DOI":"10.1007\/s10741-005-2348-y"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes 2010; 17: 199-204.","DOI":"10.1097\/MED.0b013e3283391989"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Young MJ. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 2008; 17: 174-80.","DOI":"10.1097\/MNH.0b013e3282f56854"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Arai K, Homma T, Morikawa Y, <i>et al<\/i>. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol 2015; 761: 226-34.","DOI":"10.1016\/j.ejphar.2015.06.015"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Takahashi M, Ubukata O, Homma T, <i>et al<\/i>. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150). FEBS Lett 2020; 594: 1615-23.","DOI":"10.1002\/1873-3468.13746"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Gao X, Chang J, Chang Y, <i>et al<\/i>. Esaxerenone Inhibits Renal Angiogenesis and Endothelial-Mesenchymal Transition via the VEGFA and TGF-\u03b21 Pathways in Aldosterone-Infused Mice. Int J Mol Sci 2023; 24: 11766.","DOI":"10.3390\/ijms241411766"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yamamoto H, Yoshida N, Kihara S. Esaxerenone Blocks Vascular Endothelial Inflammation Through SGK1. J Cardiovasc Pharmacol 2022; 80: 583-91.","DOI":"10.1097\/FJC.0000000000001316"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Yamashita H, Fujii M, Bessho R, Ishii Y. Effect of esaxerenone on ischaemia and reperfusion injury in rat hearts. Eur J Cardiothorac Surg 2023; 64: ezad405.","DOI":"10.1093\/ejcts\/ezad405"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kurata A, Furuie H, Ishizuka T, <i>et al<\/i>. Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study. Adv Ther 2019; 36: 1618-27.","DOI":"10.1007\/s12325-019-00956-z"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol 2018; 84: 1821-9.","DOI":"10.1111\/bcp.13616"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Moss ME, Carvajal B, Jaffe IZ. The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease. Pharmacol Ther 2019; 203: 107387.","DOI":"10.1016\/j.pharmthera.2019.06.009"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Rossello X, Ferreira JP, Pocock SJ, <i>et al<\/i>. Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. Eur J Heart Fail 2020; 22: 834-44.","DOI":"10.1002\/ejhf.1740"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Wolter NL, Jaffe IZ. Emerging vascular cell-specific roles for mineralocorticoid receptor: implications for understanding sex differences in cardiovascular disease. Am J Physiol Cell Physiol 2023; 324: C193-204.","DOI":"10.1152\/ajpcell.00372.2022"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/66\/5\/66_25-051\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:53:25Z","timestamp":1759550005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/66\/5\/66_25-051\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.25-051","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"25-051"}}